MedTrace Logo

CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)

NCT04975477 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-07-23

No results posted yet for this study

Summary

Compensated advanced chronic liver disease (cACLD) was associated with a high rate of variceal bleeding, ascites, and hepatic encephalopathy due to portal hypertension. In these patients, esophagogastroduodenoscopy and hepatic venous pressure gradient were recommended methods to evaluate portal hypertension. However, non-invasive predictors of outcomes to stratify care remains needed. Although the updated EASL guideline has recommended that patients with liver stiffness \>20kPa or platelets \<150\*10\^9/L had the high risk of decompensation, the criteria remains to be validated. This international multicenter study aims to develop a novel CHESS-SAVE score to further predict the risk of liver decompensation in cACLD patients.

Conditions

  • Compensated Advanced Chronic Liver Disease

Interventions

PROCEDURE

Esophagogasrtoduodendoscopy and liver stiffness

Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.

PROCEDURE

hepatic venous pressure gradient

A method was used to evaluate portal pressure.

Sponsors & Collaborators

  • LanZhou University

    collaborator OTHER

  • Institute of Liver and Biliary Sciences (ILBS)

    collaborator UNKNOWN

  • Zagazig University

    collaborator OTHER_GOV

  • Korea University

    collaborator OTHER

  • Ehime University Graduate School of Medicine

    collaborator OTHER

  • Hyogo Medical University

    collaborator OTHER

  • Tianjin Second People's Hospital

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • Hepatopancreatobiliary Surgery Institute of Gansu Province

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-16
Primary Completion
2021-08-16
Completion
2021-08-16

Countries

  • China
  • Egypt
  • India
  • Japan
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975477 on ClinicalTrials.gov